InvestorsHub Logo
Followers 0
Posts 194
Boards Moderated 0
Alias Born 04/14/2024

Re: None

Tuesday, 04/23/2024 10:13:11 PM

Tuesday, April 23, 2024 10:13:11 PM

Post# of 42879
Before the bankruptcy humanigen had over 5 million in cash and equivalent assets not including the ip patents and only 2 million in liabilities. That 5 million in cash and equivalent didn't include the ip lenz patent tht was generating 2.5 million licensing fees just from Austalian subsidiary.. of the 44.10 million in fake creditor claims only 1-2 million was real debt owed. the rest was fraudulent creditor claims. as no company would give credit that much and no bank will lend money to humanigen as they had no collateral and no revenue. The company could have just went to the market to raise additional investment and didn't need the bank loans. so no bank would lend money to humanigen as an unsecured lender.
The Chime and and pathogen just two 'disputed' claim which was breach of contract lawsuit was like 37 million dollars of the 44.10 million 'creditor claim and because of the lawsuits the company was not able to raise capital by issueing any equity as most biotech would do. but that was the plan. to go bankrupt and wipe out existing ipo investor equity. by auction assets in sham auction that was sold for nothing in rigged fraudulent sham auction.